{"id":"W4394689596","doi":"10.1038/s41571-024-00886-y","title":"Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","year":2024,"lang":"en","type":"review","venue":"Nature Reviews Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":98,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Clinical trial; Immune system; Blockade; Vascular endothelial growth factor; Aflibercept; Cancer research; Angiogenesis; Pharmacology; Bevacizumab; Oncology; Immunology; VEGF receptors; Internal medicine; Chemotherapy; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002814257,0.001250865,0.002576744,0.0008114954,0.0002126547,0.001886154,0.001448644,0.00144619,0.005060404],"category_scores_gemma":[0.003015415,0.0002736348,0.001261854,0.0009387316,0.0006184469,0.00152393,0.0007262899,0.005036472,0.001755859],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009870736,"about_ca_system_score_gemma":0.001425342,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009962,"about_ca_topic_score_gemma":0.00322546,"domain_scores_codex":[0.9995535,0.0001310907,0.00004939218,0.00007281044,0.0001357161,0.00005735093],"domain_scores_gemma":[0.9984813,0.000969464,0.0001261943,0.00003798904,0.0002399848,0.0001450934],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007157652,0.0001931485,0.0001592896,0.007425658,0.0003412353,0.0001354402,0.00003278379,0.0008239684,0.001264467,0.00418588,0.07241751,0.9123049],"study_design_scores_gemma":[0.001298629,0.001016152,0.0009984185,0.007802124,0.0006925383,0.0007534091,0.00005166262,0.0003302873,0.0007223648,0.004935279,0.9813638,0.00003539701],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003538297,0.9949558,0.0004507365,0.001726471,0.0006611493,0.00003098923,0.0001158416,0.000025227,0.001679953],"genre_scores_gemma":[0.002698308,0.991179,0.0008180946,0.003145728,0.0005607635,0.00006348525,0.0002196484,0.0000152009,0.001299705],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005060404,"threshold_uncertainty_score":0.01692873,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2805150098880188,"score_gpt":0.5924041186574771,"score_spread":0.3118891087694583,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}